» Articles » PMID: 31243265

LINC01355 Suppresses Breast Cancer Growth Through FOXO3-mediated Transcriptional Repression of CCND1

Overview
Journal Cell Death Dis
Date 2019 Jun 28
PMID 31243265
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, several protein-coding tumor suppressors localized at 1p36 have been reported. In the present work, we focus on functional long non-coding RNAs (lncRNAs) embedded in this locus. Small interfering RNA was used to identify lncRNA candidates with growth-suppressive activities in breast cancer. The mechanism involved was also explored. LINC01355 were downregulated in breast cancer cells relative to non-malignant breast epithelial cells. Overexpression of LINC01355 significantly inhibited proliferation, colony formation, and tumorigenesis of breast cancer cells. LINC01355 arrested breast cancer cells at the G0/G1 phase by repressing CCND1. Moreover, LINC01355 interacted with and stabilized FOXO3 protein, leading to transcriptional repression of CCND1. Importantly, LINC01355-mediated suppression of breast cancer growth was reversed by knockdown of FOXO3 or overexpression of CCND1. Clinically, LINC01355 was downregulated in breast cancer specimens and correlated with more aggressive features. There was a negative correlation between LINC01355 and CCND1 expression in breast cancer samples. LINC01355 acts as a tumor suppressor in breast cancer, which is ascribed to enhancement of FOXO3-mediated transcriptional repression of CCND1. Re-expression of LINC01355 may provide a potential therapeutic strategy to block breast cancer growth and progression.

Citing Articles

POGZ targeted by LINC01355/miR-27b-3p retards thyroid cancer progression via interplaying with MAD2L2.

Lu J, Zhou X, Zhu H, Zou M, Liu L, Li X 3 Biotech. 2025; 15(4):79.

PMID: 40071126 PMC: 11890915. DOI: 10.1007/s13205-025-04231-7.


Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review.

Afroze N, Sundaram M, Haque S, Hussain A Discov Oncol. 2025; 16(1):122.

PMID: 39912983 PMC: 11803034. DOI: 10.1007/s12672-025-01848-1.


The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications.

Hu Z, Yuan L, Yang X, Yi C, Lu J Front Oncol. 2024; 14:1332528.

PMID: 38725621 PMC: 11079149. DOI: 10.3389/fonc.2024.1332528.


Long Intergenic Non-Coding RNAs of Human Chromosome 18: Focus on Cancers.

Ershov P, Yablokov E, Mezentsev Y, Ivanov A Biomedicines. 2024; 12(3).

PMID: 38540157 PMC: 10968066. DOI: 10.3390/biomedicines12030544.


Role and regulation of FOXO3a: new insights into breast cancer therapy.

Mei W, Mei B, Chang J, Liu Y, Zhou Y, Zhu N Front Pharmacol. 2024; 15:1346745.

PMID: 38505423 PMC: 10949727. DOI: 10.3389/fphar.2024.1346745.


References
1.
Royce M, Bachelot T, Villanueva C, Ozguroglu M, Azevedo S, Cruz F . Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018; 4(7):977-984. PMC: 5885212. DOI: 10.1001/jamaoncol.2018.0060. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

3.
Karadedou C, Gomes A, Chen J, Petkovic M, Ho K, Zwolinska A . FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 2011; 31(14):1845-58. PMC: 3232453. DOI: 10.1038/onc.2011.368. View

4.
Sisci D, Maris P, Cesario M, Anselmo W, Coroniti R, Trombino G . The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle. 2013; 12(21):3405-20. PMC: 3895429. DOI: 10.4161/cc.26421. View

5.
Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R . Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast Cancer Res. 2014; 16(6):491. PMC: 4303201. DOI: 10.1186/s13058-014-0491-x. View